Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
- PMID: 17196053
- DOI: 10.4088/jcp.v67n1110
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Abstract
Background: Anecdotal reports suggest that psychedelic agents may relieve symptoms of obsessive-compulsive disorder (OCD). This modified double-blind study investigated the safety, tolerability, and clinical effects of psilocybin, a potent 5-HT(1A) and 5-HT(2A/2C) agonist, in patients with OCD.
Method: Nine subjects with DSM-IV-defined OCD and no other current major psychiatric disorder participated in up to 4 single-dose exposures to psilocybin in doses ranging from sub-hallucinogenic to frankly hallucinogenic. Low (100 microg/kg), medium (200 microg/kg), and high (300 microg/kg) doses were assigned in that order, and a very low dose (25 microg/kg) was inserted randomly and in double-blind fashion at any time after the first dose. Testing days were separated by at least 1 week. Each session was conducted over an 8-hour period in a controlled environment in an outpatient clinic; subjects were then transferred to a psychiatric inpatient unit for overnight observation. The Yale-Brown Obsessive Compulsive Scale (YBOCS) and a visual analog scale measuring overall obsessive-compulsive symptom severity were administered at 0, 4, 8, and 24 hours post-ingestion. The Hallucinogen Rating Scale was administered at 8 hours, and vital signs were recorded at 0, 1, 4, 8, and 24 hours after ingestion. The study was conducted from November 2001 to November 2004.
Results: Nine subjects were administered a total of 29 psilocybin doses. One subject experienced transient hypertension without relation to anxiety or somatic symptoms, but no other significant adverse effects were observed. Marked decreases in OCD symptoms of variable degrees were observed in all subjects during 1 or more of the testing sessions (23%-100% decrease in YBOCS score). Repeated-measures analysis of variance for all YBOCS values revealed a significant main effect of time on Wilks lambda (F = 9.86, df = 3,3; p = .046), but no significant effect of dose (F = 2.25, df = 3,3; p = .261) or interaction of time and dose (F = 0.923, df = 9,45; p = .515). Improvement generally lasted past the 24-hour timepoint.
Conclusions: In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.
Similar articles
-
Psilocybin and Obsessive Compulsive Disorder.J Psychoactive Drugs. 2014 Nov-Dec;46(5):393-5. doi: 10.1080/02791072.2014.963754. J Psychoactive Drugs. 2014. PMID: 25364991
-
Psilocybin for the Treatment of Obsessive-Compulsive Disorders.Curr Top Behav Neurosci. 2022;56:247-259. doi: 10.1007/7854_2021_279. Curr Top Behav Neurosci. 2022. PMID: 34784024 Review.
-
N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.CNS Drugs. 2015 Sep;29(9):801-9. doi: 10.1007/s40263-015-0272-9. CNS Drugs. 2015. PMID: 26374743 Clinical Trial.
-
Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial.Front Psychiatry. 2023 Apr 25;14:1178529. doi: 10.3389/fpsyt.2023.1178529. eCollection 2023. Front Psychiatry. 2023. PMID: 37181888 Free PMC article.
-
[Classic psychedelic drugs and their potential therapeutic effect].Ugeskr Laeger. 2017 Sep 11;179(37):V01170005. Ugeskr Laeger. 2017. PMID: 28918777 Review. Danish.
Cited by
-
Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.Psychopharmacology (Berl). 2024 May 14. doi: 10.1007/s00213-024-06599-5. Online ahead of print. Psychopharmacology (Berl). 2024. PMID: 38743110 Review.
-
In vitro and in vivo metabolism of psilocybin's active metabolite psilocin.Front Pharmacol. 2024 Apr 29;15:1391689. doi: 10.3389/fphar.2024.1391689. eCollection 2024. Front Pharmacol. 2024. PMID: 38741590 Free PMC article.
-
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.BMJ. 2024 May 1;385:e078084. doi: 10.1136/bmj-2023-078084. BMJ. 2024. PMID: 38692686 Free PMC article.
-
Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms.Psychopharmacology (Berl). 2024 Apr 30. doi: 10.1007/s00213-024-06585-x. Online ahead of print. Psychopharmacology (Berl). 2024. PMID: 38687360
-
In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials.Psychopharmacology (Berl). 2024 Jun;241(6):1101-1110. doi: 10.1007/s00213-024-06598-6. Epub 2024 Apr 29. Psychopharmacology (Berl). 2024. PMID: 38683460 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous